| abstract |
A novel class or family of TGF-β-binding proteins is disclosed. Determinations for selection of molecules for increasing bone calcification and methods for using such molecules are also disclosed. In particular, there are provided compositions and methods related to antibodies that specifically bind TGF-β-binding proteins. These methods and compositions are associated with alteration of bone density by interfering with the interaction between TGF-β-binding protein sclerostin and a member of the TGF-β superfamily, in particular bone morphogenic protein. Increased bone density has utility in diseases and conditions in which low bone density characterizes the condition, such as osteopenia, osteoporosis, and bone fractures. |